Beta Bionics, Inc. Class Action Reminder - Robbins LLP Encourages BBNX Investors to Contact the Firm for Information About Their Rights

Robbins LLP reminds investors of a class action lawsuit against Beta Bionics (BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company failed to disclose serious FDA concerns about device malfunctions causing dangerously high insulin doses and hypoglycemic events. Stock fell from $31.99 to $12.89 per share between January and February 2026 following FDA warning letter disclosures.